Pharmaceuticals Europe

Europe Spinal Muscular Atrophy Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Europe Spinal Muscular Atrophy Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Europe · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $929.0 Mn Placeholder estimate
Estimate 2025 $976.4 Mn 19.3% of the global market
Projected 2034 $1.53 Bn 56.5% Adds $551.3 Mn over 9 forecast years
CAGR 2025–2034 5.1% Faster than 28% of 186 Pharmaceuticals markets here
Key players 5
  • Europe is 19.31% of the global market.
  • Among regions, the largest is North America at $2.30 Bn.
  • Fastest growing: Africa at 7.8% a year.
  • Europe ranks 3rd of 6 by size among regions.

Market size projection

Europe

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$551.3 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Spinal Muscular Atrophy Treatment Market market size by year, Europe
YearMarket sizeChange that yearSince 2025
2024 (estimate) $929.0 Mn — —
2025 (base) $976.4 Mn +$47.4 Mn —
2026 (forecast) $1.03 Bn +$49.8 Mn +5.1%
2027 (forecast) $1.08 Bn +$52.3 Mn +10.5%
2028 (forecast) $1.13 Bn +$55.0 Mn +16.1%
2029 (forecast) $1.19 Bn +$57.8 Mn +22%
2030 (forecast) $1.25 Bn +$60.8 Mn +28.2%
2031 (forecast) $1.32 Bn +$63.9 Mn +34.8%
2032 (forecast) $1.38 Bn +$67.1 Mn +41.7%
2033 (forecast) $1.45 Bn +$70.5 Mn +48.9%
2034 (forecast) $1.53 Bn +$74.1 Mn +56.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Europe Spinal Muscular Atrophy Treatment Market Analysis at a glance
Market size, 2025$976.4 Mn placeholder estimate
Forecast, 2034$1.53 Bn placeholder estimate
Growth (CAGR), 2025–20345.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTreatment, type and end user (see all)
Key playersBiogen Inc, Novartis AG, Roche, Scholar Rock, Biohaven (see all)
Regulator in EuropeEMASource: European Medicines Agency. Checked 14 Nov 2026.
Active clinical trials50 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Europe Spinal Muscular Atrophy Treatment Market Analysis Executive Summary

Spinal muscular atrophy treatments, including gene therapy and RNA medicines, stop the loss of muscle strength in this rare genetic disease.

Key segments of the spinal Muscular Atrophy Treatment market include treatment (Gene Therapy, Antisense Oligonucleotides and Oral Splicing Modifiers) and type (Type 1, Type 2 and Type 3).

Bar chart: Europe Spinal Muscular Atrophy Treatment market size, 2024–2034, placeholder estimates. $929.0 Mn in 2024, $976.4 Mn in 2025 and $1.53 Bn in 2034, 5.1% CAGR.
Europe Spinal Muscular Atrophy Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Europe Spinal Muscular Atrophy Treatment Market Dynamics

Market Growth Drivers

Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the spinal Muscular Atrophy Treatment market. More countries now have national rare disease plans.

Opportunity

Newborn genome screening, gene therapies and access programmes in emerging markets give the spinal Muscular Atrophy Treatment market strong growth.

Market Restraints

Very small patient numbers, long diagnosis delays, high treatment prices and limited specialist centres hold back the spinal Muscular Atrophy Treatment market.

Competitive Landscape for Spinal Muscular Atrophy Treatment Market in Europe

The spinal Muscular Atrophy Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Spinal Muscular Atrophy Treatment Market in Europe

Spinal Muscular Atrophy Treatment in Europe: rules, payment and research

In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).⁠[1] In the countries we cover here, medicines are approved by ANSM (France)⁠[2], BfArM (Germany)⁠[3], AIFA (Italy)⁠[4], Ministry of Health (Russia)⁠[5], AEMPS (Spain)⁠[6], MHRA (UK)⁠[7], CBG-MEB (Netherlands)⁠[8], FAMHP (Belgium)⁠[9], Swissmedic (Switzerland)⁠[10], Läkemedelsverket (Sweden)⁠[11], Danish Medicines Agency (Denmark)⁠[12], URPL (Poland)⁠[13] and TITCK (Turkey)⁠[14]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.⁠[15] ClinicalTrials.gov lists 50 studies on Spinal Muscular Atrophy Treatment that are recruiting, active or about to start in Europe.⁠[16]

[1] European Medicines Agency. Checked 14 Nov 2026.

[2] ANSM, French medicines agency. Checked 14 Nov 2026.

[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[4] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.

[5] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.

[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[8] Medicines Evaluation Board (CBG-MEB). Checked 19 Nov 2026.

[9] Federal Agency for Medicines and Health Products (FAMHP). Checked 19 Nov 2026.

[10] Swissmedic. Checked 19 Nov 2026.

[11] Swedish Medical Products Agency (Läkemedelsverket). Checked 19 Nov 2026.

[12] Danish Medicines Agency. Checked 19 Nov 2026.

[13] Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). Checked 19 Nov 2026.

[14] Turkish Medicines and Medical Devices Agency (TITCK). Checked 19 Nov 2026.

[15] European Commission, health technology assessment. Checked 14 Nov 2026.

[16] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for spinal Muscular Atrophy Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Spinal Muscular Atrophy Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Spinal Muscular Atrophy Treatment in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Spinal Muscular Atrophy Treatment market in Europe?
Placeholder estimate: about $976.4 Mn in 2025, rising to about $1.53 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Spinal Muscular Atrophy Treatment market in Europe growing?
Placeholder estimate: about 5.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Spinal Muscular Atrophy Treatment market report cover?
The report splits the market by treatment (Gene Therapy, Antisense Oligonucleotides, Oral Splicing Modifiers), type (Type 1, Type 2, Type 3) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Spinal Muscular Atrophy Treatment market?
Key players include Biogen Inc, Novartis AG, Roche, Scholar Rock and Biohaven.
What is driving the Spinal Muscular Atrophy Treatment market?
Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the spinal Muscular Atrophy Treatment market. More countries now have national rare disease plans.
Who regulates Spinal Muscular Atrophy Treatment in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on Spinal Muscular Atrophy Treatment are running in Europe?
50 studies are recruiting, active or about to start in Europe, counted across the 13 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on Spinal Muscular Atrophy Treatment?
PubMed lists 20 papers on Spinal Muscular Atrophy Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Europe

See all

Related on rare diseases and brain and nerves

See the topic